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Abstract 
The recognition and treatment of psychosis in persons with epilepsy (PWE) is 
recommended with the apparent dilemma between treating psychosis and opening the 
possibility of exacerbating seizures. The pooled prevalence estimate of psychosis in 
PWE is 5.6%. It has been proposed that a ‘two hit’ model, requiring both aberrant 
limbic activity and impaired frontal control, may account for the wide range of clinical 
phenotypes. The role of anticonvulsant drugs in psychosis in PWE remains unclear. 
Alternating psychosis, the clinical phenomenon of a reciprocal relationship between 
psychosis and seizures, is unlikely to be an exclusively anticonvulsant-specific 
phenomenon but rather, linked to the neurobiological mechanisms underlying seizure 
control. Re-evaluation of anticonvulsant treatment, including the agent/s being used and 
degree of epileptic seizure control is recommended. The authors found very few 
controlled studies to inform evidence-based treatment of psychosis in PWE. However, 
antipsychotics and benzodiazepines are recommended as the symptomatic clinical 
treatments of choice for postictal and brief interictal psychoses. The general principle of 
early symptomatic treatment of psychotic symptoms applies in epilepsy-related 
psychoses, as for primary psychotic disorders. In the authors’ experience, low doses 
antipsychotic medications do not significantly increase clinical risk of seizures in PWE 
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being concurrently treated with an efficacious anticonvulsant regimen. 
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Introduction 
Rational pharmacological treatment of psychoses in PWE should ideally be based upon 
the mechanisms linking the two disorders. However, the neurobiological understanding 
of these mechanisms remains incomplete, with absence of a satisfactory explanatory 
model to guide drug treatment. The empirical evidence is also insufficient. These 
guidelines for the treatment of Psychoses in PWE (Figure 1) are therefore based on the 
cumulative clinical experience of the authors and some systematic study.  
A two-step procedure, not necessarily consecutive, is recommended. The first step 
requires reevaluation of the antiepileptic treatment, an integral and under-recognized 
component of treatment in the authors’ view. The second step requires initiation of 
pharmacotherapy including antipsychotic drugs (APD) and benzodiazepines. In this 
review, we discuss contextually-relevant translational neuroscience in Psychoses in PWE, 
recommended pharmacotherapy, and closely related topics such as alternating psychosis 
and the impact on seizure threshold of APD. Whilst the level of evidence remains low, 
partly due to challenges inherent in performing multisite randomized control trials, 
prompt empirically based treatment of patients with psychosis is strongly recommended. 
Untreated psychotic episodes in PWE can have devastating effects on the patients and 
those supporting them [1]  
Clinical classification of Psychoses in PWE 
Psychotic disorders are defined by the presence of delusions, hallucinations, disorganized 
thinking, grossly disorganized and/or abnormal motor behavior, and may include 
negative symptoms (DSM-5). Consciousness is typically preserved. Psychoses in PWE 
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can be clinically characterized into two main categories depending upon the temporal 
relationship of symptom emergence to seizures: Interictal Psychosis (IIP) and Postictal 
Psychosis (PIP) [2]. IIP refers to psychosis that occurs in clear consciousness in PWE 
with temporal onset not during or immediately following a seizure. A personal or family 
history of psychosis, intellectual disability, and the sum of previous seizures are 
recognized vulnerability factors [3]. IIP can be further sub-classified according to 
duration (e.g., acute/brief/transient or chronic) and presumed etiology (e.g., drug-induced 
or forced normalization); however, these sub-classifications have not been validated. An 
individual with epilepsy may exhibit differing forms of IIP at different time points, e.g., 
drug-induced or non–drug induced, and acute or chronic [2]. Several epilepsy-related 
variables are considered pathogenically relevant in IIP including epilepsy type and 
seizure characteristics. Persons with focal epilepsy, particularly those who have temporal 
lobe seizures with impaired awareness, have a higher risk of IIP than those with 
generalized epilepsy [3]. Antiepileptic drugs (AEDs) and seizure frequency are also 
likely to have a significant association in the development of IIP. Altering the AED may 
consequently prevent or treat IIP in some cases.   
Postictal psychosis (PIP) is a specific syndrome with clear temporal relationship 
between the acute onset of psychotic symptoms and the precipitating bout of focal 
7 
 
impaired awareness seizures or generalized seizures. There is currently no diagnostic 
definition for PIP in DSM-5 and it would be coded as “Psychotic disorder due to another 
medical condition”. The following specific diagnostic criteria have however been 
proposed: (1) Onset of psychosis within 1 week post seizure(s); (2) Psychosis duration 
exceeding 15 hours but less than 2 months; (3) Presence of one or more of the following: 
delusions, hallucinations, impaired consciousness, bizarre or disorganized behavior, 
formal thought disorder or affective changes; and (4) No evidence of AED toxicity, 
non-convulsive status epilepticus, recent head trauma, alcohol, or drug intoxication or 
withdrawal or chronic psychotic disorder that would better account for the current clinical 
presentation [4]. The presence of a lucid interval between the last seizure and the onset of 
psychotic symptoms rules out a simple confusional state. The clinical course of PIP is 
typically characterized by remission of the psychotic symptoms over several days (mean: 
1 week) [5], with or without any treatment. Pre-psychotic EEG abnormalities persist 
during the psychosis. Risk factors for PIP include: long standing focal epilepsy, 
extratemporal onset, bilateral epileptiform activity, secondary generalization, slowing of 
the EEG background activity, and personal or family history of psychiatric disorders [6]. 
Brain MRI frequently shows structural abnormalities [6].  
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In order to understand the relationship between seizures and psychosis, PIP, IIP and 
alternating psychoses (in which an altered mental state arises with seizure frequency 
decrease or even control of the seizures) require a strong neurobiological model which is 
still lacking [1,7].  
Epidemiology of Psychoses in PWE 
In community-based studies of epilepsy that have examined the prevalence of psychosis, 
3.1% to 9.2% [8,9,10,11] have been reported to have psychosis; 0.7% to 3.3% of all PWE 
have affective psychosis, [10,12] and 0.7% to 1.2% have schizophrenia-like psychosis 
[8,9,10,11].
  
A systematic study demonstrated that psychotic symptoms (hallucinations 
and delusions in full consciousness which do not occur as seizure symptoms) are present 
in about 5.6 % of patients with epilepsy (overall pooled prevalence) [13].
 
When PWE are 
compared to controls, psychotic disorders are 3-fold or more common in prevalent 
epilepsy [10, 11].
 
Studies examining the temporal relationship between 
psychosis/schizophrenia and epilepsy have been conducted in large population-based 
registries because both disorders are relatively rare. The cumulative data suggest a 
bidirectional relationship between incident epilepsy and incident psychosis. Psychosis 
was associated with an increased risk for developing epilepsy in a Swedish study of 
hospitalized psychosis (OR=2.7; 95% CI 1.6-4.8) (14). In a UK general practice research 
database [15], psychosis was associated with a statistically significant increased risk for 
developing epilepsy in each of the three years before epilepsy onset (IRR=15.7, 8.5 and 
7.7 in the 3
rd
-1
st
 year before epilepsy onset).  
In the same UK study
 
[15], incident epilepsy was associated with a statistically 
significant increased risk of developing a first ever psychosis in each of the three years 
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after epilepsy onset (IRR=10.9, 4.8 and 4.0 respectively). Similar results were seen when 
epilepsy of unknown etiology was examined. In two record linkage studies in Denmark, 
the incidence of non-organic non-affective psychoses was examined, excluding 
intellectual disability and/or substance misuse [16].
 
The standardized incidence ratio was 
significantly increased 1.48-fold for schizophrenia (95% CI: 1.12-1.92), 2.04-fold for 
non-affective psychosis (95% CI: 1.69-2.45) and 2.30-fold for non-organic non-affective 
psychoses (95% CI: 2.02-2.59).  There were no differences by gender or seizure type. A 
second Danish registry study compared epilepsy to controls [17]. Epilepsy was associated 
with a 2.18-fold increased risk for schizophrenia (95% CI: 2.20-2.80) in the absence of a 
family history of psychosis, an important exclusion because family history is one of the 
established factors for an increased risk for schizophrenia in PWE [13]. The risk for 
schizophrenia-like psychosis was increased 2.93-fold (95% CI: 2.69-3.20). There was no 
gender difference but increasing age was associated with a statistically significant 
increased risk for developing schizophrenia (Relative Risk: 2.03, 2.28, and 4.00 for 
people aged 15-24, 25-34 and >35 years), suggesting that the median age at onset of 
schizophrenia after epilepsy is greater than the onset of 22 years reported in the general 
population [18]. In families with a history of psychosis and a family history of epilepsy, 
there was an increased risk for schizophrenia and schizophrenia-like psychosis.  
In addition, several population-based studies have suggested the existence of a 
bidirectional relationship between epilepsy and several psychiatric disorders including, 
ADHD, and primary mood, anxiety, and psychotic disorders. Not only are PWE at higher 
risk of developing one of these psychiatric disorders, but patients with one of these 
primary psychiatric disorders are at greater risk of developing epilepsy. This phenomenon 
is of great importance in the management of these psychiatric comorbidities, as the 
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occurrence of seizures in a patient treated with psychotropic drug is not necessarily 
drug-related [19]. Although, in epidemiological terms, the relationship between epilepsy 
and psychosis might be considered to be bidirectional, this makes no assumption about 
the causation; in at least some cases it is likely that both conditions result from a common 
underlying cause, although whether that cause might be genetic, environmental or some 
combination of factors remains to be elucidated. 
Neurobiology of Psychoses in PWE  
Whilst explanatory models still remain speculative, there is some evidence that supports 
aberrant biochemical and neuroanatomic processes in the epileptic psychoses. However, 
it is uncertain whether such processes reflect pathophysiological cause, effect or a 
common aberrant substrate, given the cross-sectional nature of available data. A recent 
systematic review
 
[20] found the following factors to be consistently associated with 
psychosis in temporal lobe epilepsy (TLE): early onset of epilepsy; history of status 
epilepticus, often nonconvulsive; unilateral or bilateral hippocampal sclerosis; cell loss in 
the CA1 hippocampal region; left hippocampal abnormalities. The left hippocampal 
abnormalities were specifically reduced N-acetylaspartate (NAA, an intraneuronal amino 
acid utilised as a proxy measure of cerebral damage) and gray matter, (this association is 
also reported in non-epileptic psychotic disorders) and more impaired current cognitive 
performance. It is noteworthy that reports from intracranial depth electrode monitoring 
support the assertion that PIP occurs in a true postictal state, rather than reflecting 
subclinical persistent epileptogenic activity in deep brain structures [21]. 
Dysfunction in limbic networks has been widely hypothesized as the anatomical 
substrate for psychosis. However, more widespread cerebral changes are likely to be 
required for its development. Prefrontal dysfunction with inadequate inhibitory 
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modulation of limbic activity in schizophrenic psychosis has been supported by animal 
models [22].
  
It has been speculated that frontal lobe structure, function and intact 
frontal-limbic networks might be of etiological importance in epileptic psychoses. 
Perfusion SPECT studies have demonstrated abnormalities in frontal and temporal 
regions in PIP suggesting that neuronal network dysfunction remote from the 
epileptogenic region is etiologically relevant [23,24]. A ‘two hit’ model of psychosis in 
epilepsy, requiring both aberrant limbic activity and impaired frontal control, may explain 
some of the wide range in clinical phenotypes of epileptic psychoses [25].  
The repeated release of neurotransmitters, including acetylcholine, 
catecholamines, serotonin, opiates, adenosine and nitrous oxide during seizures is likely 
to pathogenically alter the function of postsynaptic receptors in the postictal state [26].
 
Altered monoamine receptor sensitivity has been supported by SPECT findings of low 
levels of striatal D2 in patients with peri-ictal psychosis [27].
 
GABAergic tone is central 
to seizure-related inhibitory mechanisms and its role in epilepsy-related psychoses is 
supported by demonstrable alterations in benzodiazepine receptors and favorable 
therapeutic response to benzodiazepines [28]. Similarly, there is strong evidence for the 
centrality of glutamatergic activity within an inhibition-excitation model of psychosis; 
NMDA receptor agonism is proconvulsant, NMDA receptor antagonism (with ketamine 
or PCP) is propsychotic and there is substantive evidence for glutamate receptor 
dysfunction in schizophrenia. Dopaminergic activity can also be considered within an 
excitation-inhibition paradigm with dopamine antagonism being proconvulsant and 
antipsychotic. Support for a kindling relationship between seizures and psychosis now 
includes a direct link in animal models between increased hippocampal activity in TLE 
12 
 
and hyper-responsivity of the dopamine system. A significant increase in ventral 
tegmental dopamine neuron firing was observed after recurrent seizures in rats [29].  
Do specific antiepileptic drugs increase the risk of Psychoses in PWE?  
The long-standing debate with two sharply opposing hypotheses regarding the 
relationship between Psychoses in PWE and AEDs remains unresolved. Some authors 
have strongly advocated that any potent AED can precipitate psychosis precisely because 
of the potent anticonvulsant effects and that a subgroup of patients is particularly 
vulnerable to dramatic seizure reduction, irrespective of the AED used. In contrast, there 
are reports of psychotic symptoms specifically after exposure to certain AEDs 
[30,31,32,33] (including; ethosuximide [34], topiramate [35], felbamate [36], 
levetiracetam [37], zonisamide [38] ,vigabatrin [39],
 
tiagabine [40] and lacosamide [41]. 
Whether they are specifically causal in the development of psychosis or not remains open 
to debate for reasons stated above. Psychosis related to lamotrigine remains controversial, 
with many studies unable to demonstrate an association [42].  
Several authors have reported case-control studies or multiple case reports with 
special attention to AED-related psychosis. A summary of these studies is as follows. 
Recent modification of AEDs was found in 34 to 38% of PWE presenting with psychosis 
[30,31];
 
AED-related psychosis was more closely related to a decrease in seizure 
frequency in comparison with drug-independent psychosis [31,32]
. 
AED-related 
psychosis was more likely to be transient in comparison with drug-independent 
psychosis [30,31]. Medial temporal lobe involvement and genetic predisposition are 
overrepresented irrespective of the drug involved [32] in persons with AED-related 
psychosis. Frank psychosis has been reported more frequently following the initiation of 
specific AEDs including phenytoin, zonisamide, topiramate and levetiracetam when 
13 
 
compared with other AEDs [31,32,37,42]. While these data appear conflicting prima 
facie, the disparity is resolved when the rarity of Psychosis in PWE responsive to 
first-line AED is accounted for. Even potent AEDs, which have a statistically greater 
tendency to be associated with psychosis when resulting in seizure freedom, do not 
typically cause psychosis in first-line AED treatment-responsive patients. Patients with 
epilepsy who fail to respond to second- or third-line AED treatment, or with a genetic 
predisposition to psychosis, are potentially more vulnerable to AEDs with negative 
psychotropic properties, which might precipitate an episode of psychosis. Finally, in the 
longer term, intractable epilepsy patients become psychotic with minimal change in 
epileptic activity, including not only AEDs but also surgical intervention or vagus nerve 
stimulation [43].  
Psychosis could be a direct effect of the AED (pharmacological consequence, drug 
toxicity, drug withdrawal), or associated with the forced normalization phenomenon and 
its clinical counterpart, the alternating psychosis. Although speculative, psychosis as a 
complication of the administration of an AED may appear only in association with 
structural abnormalities and neurochemical dysfunctions involving the limbic circuit 
[42,44].   
 Among the known associations of psychiatric symptoms in PWE, the use of 
AEDs is just one of the factors, alongside individual factors directly related to the patient 
and the specific individual epileptic disorder [33].
  
AEDs do not appear to be the single 
determinant of psychosis in PWE. Genetically determined individual susceptibility in 
conjunction with severity of the patient's epilepsy is probable additional factors [45]. 
Despite the lack of convincing evidence, in clinical practice it is advised that the 
aforementioned specific AEDs be used with caution in patients with a personal and/or 
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positive family history of psychosis, patients with difficult to control epilepsy (e.g., TLE), 
particularly in high doses and or with rapid titration regimens [33]. 
The problem of alternating psychosis 
Alternating psychoses, and the so-called “forced normalization” phenomenon, have been 
a matter of debate ever since the first reports of Heinrich Landolt during the 1950s. 
Landolt reported EEG investigations of patients with epilepsy and paroxysmal 
psychiatric disorders, describing a group who had productive (i.e. with hallucinations) 
psychotic episodes with “forced normalization” of the EEG [46]. The abnormal EEGs of 
these patients improved or normalized during the time that they were psychotic. 
Subsequently, Tellenbach introduced the term “alternating psychoses” for the clinical 
phenomenon of the reciprocal relationship between abnormal mental states and seizures, 
which did not, as Landolt’s term did, rely on EEG findings [47]. 
Since the early observations of Landolt, a number of patients with alternating 
psychosis have been documented, placing their existence beyond doubt. An association 
with the prescription of all AEDs was noted [48],
 
suggesting that this is not a 
drug-specific phenomenon but rather linked to the neurobiological mechanisms 
underlying seizure control. A case of an alternating psychosis secondary to vagus nerve 
stimulation has been documented [49] and it is likely that the forced normalization 
phenomenon plays a role in patients who develop de novo psychosis following successful 
epilepsy surgery. 
For many years, there has been vigorous debate on whether there is an epilepsy 
syndrome most commonly associated with the forced normalization phenomenon. 
Initially, drug-refractory focal epilepsies was claimed to be the prototype but subsequent 
literature on alternative psychoses seemed to favor generalized epilepsies [50].
 
In fact, in 
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1985 Trimble found that idiopathic generalized epilepsy was most frequently associated 
with the forced normalization phenomenon [51]. Nowadays, there is general agreement 
that the forced normalization phenomenon occurs with both generalized and focal 
epilepsy, but is rare in patients with mainly generalized tonic-clonic seizures (e.g. 
idiopathic generalized epilepsy with tonic-clonic seizures of awakening) and in focal 
epilepsies outside the temporal lobe [48]. 
Pharmacotherapy for brief and chronic interictal psychosis (IIP)  
Evidence for the treatment of IIP is limited, as evidenced by a recent Cochrane systematic 
review [52], which found only one small randomized controlled trial with insufficient 
power. Expert opinion is that antipsychotics and benzodiazepines are the treatment of 
choice for brief IIP [2]. Evidence on the relative efficacy of antipsychotics in brief IIP is 
also limited. In general, psychotic symptoms are better managed earlier rather than later 
[53]. When patients have mild psychotic symptoms or do not consent to 
psychopharmacological treatment, they can be offered psychosocial interventions, or be 
carefully monitored. One of the basic approaches to IIP episodes is to reduce AED 
polypharmacy and optimize the regimen [2]. When psychotic symptoms result in serious 
distress and/or psychosocial disturbance, psychopharmacological treatment is indicated. 
The first step in the treatment of chronic IIP is accurate symptom detection and 
diagnosis [54].
 
In the early phase of an episode of IIP, it is difficult to predict the 
duration of the psychotic episode. Approximately 75% of all episodes of IIP last for one 
month or longer, which some authors have regarded as chronic [54].
 
Because the 
majority of episodes of IIP observed are recurrent, the boundary between the duration of 
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brief and chronic subtypes is often drawn arbitrarily. Brief, in addition to chronic, 
episodes of IIP may require longer-term APD treatment similar to that for primary 
schizophrenia and should be considered long-term following remission [55].  
Pharmacotherapy for post-ictal psychosis (PIP) 
Florid episodes of PIP may require consideration of admission to a mental health unit 
and delay in therapeutic intervention may be associated with high risk behaviors to self 
and others [56,57,58]. Although the evidence is less compelling than in IIP, in both the 
initial and middle stages of PIP, sedative drugs are typically indicated, as they can abort 
or alleviate symptoms of PIP. Some experts have recommended benzodiazepines [59], 
while others prefer a combination of both benzodiazepines and antipsychotics [57]. In 
most cases, the authors’ advise that effective sedation be prioritized as supported by 
Devinsky, 2008 [60]. 
In patients without severe symptoms, the administration of benzodiazepines may 
suffice. However, if increasing excitability emerges in the ensuing twenty-four hours, 
supplementary administration of antipsychotics may be necessary. In this clinical setting, 
benzodiazepines alone may precipitate paradoxical excitement and are not as potent as 
antipsychotics for rapid tranquillization of violent or agitated patients in a psychiatric 
emergency [61,62]. Paradoxically, ECT or repetitive transcranial magnetic stimulation 
have been reported as efficacious in terminating violent episodes of PIP in exceptional 
cases [63,64].  
Efficacy, adverse events, and interactions of antipsychotic drugs (APDs) in PWE 
There is no evidence to support preferential initiation of any one specific APD in 
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psychosis in PWE when equivalent doses are used [65], given the absence of randomized 
control trials specifically examining efficacy and tolerability of APDs in PWE. APDs 
should be selected with consideration of the balance between pharmacological profiles, 
efficacy, and adverse effects [2]. The clinical phenotype of psychotic phenomenon, which 
may vary considerably, might also warrant consideration [66].
 
APDs are predominantly 
effective in the symptomatic treatment of positive psychiatric symptoms, (e.g., 
delusions, hallucinations, formal thought disorder and bizarre behavior). They are less 
effective in the symptomatic treatment of negative psychiatric symptoms, (e.g., negative 
formal thought disorder, blunted affect, and apathy). In practice, atypical neuroleptics 
with few motor side-effects such as risperidone can be used as first choice: start low and 
go slow. 
There are special considerations such as interactions with anticonvulsants, the 
profile of adverse events and multiple clinical phenotypes of the psychotic phenomenon 
[66,67]. In addition to possible proconvulsant effects of APD, as discussed later, 
clinicians must also consider the pharmacokinetic and pharmacodynamic interactions 
between anticonvulsants and antipsychotics [68]. Certain enzyme-inducing AEDs can 
increase the clearance of psychotropic drugs metabolized in the liver, including 
first-generation antipsychotics (chlorpromazine, fluphenazine and haloperidol) and 
atypical antipsychotics (including clozapine, olanzapine, risperidone (with the exception 
of phenytoin which inhibits risperidone clearance), quetiapine, aripiprazole and 
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ziprasidone) [19]. In contrast, valproic acid has been reported to decrease the clearance of 
antipsychotic drugs (clozapine, olanzapine, quetiapine) [19]. Conversely, several 
psychotropic drugs can inhibit the clearance of some enzyme-inducing AEDs, in 
particular phenytoin and carbamazepine. These psychotropic drugs include some of the 
first-generation (haloperidol and loxapine) and second-generation (risperidone, 
quetiapine) APDs [19]. Carbamazepine reduces the plasma levels of all antipsychotics. 
This interaction is particularly evident for quetiapine which is predominantly 
metabolized by CYP 3A4 [69]. All of these interactions should be considered on an 
individual basis [19,69]. 
The main adverse effects of APDs include sedation, weight gain and metabolic 
syndrome, cardiovascular effects, hyperprolactinemia, sexual dysfunction, and 
extrapyramidal symptoms. APD titration procedures are to start at a low dose, titrate 
gradually to a minimum therapeutic dose, and continue at a fixed therapeutic dose for a 
sufficient period of time. Patients with particular conditions, such as distinct brain 
damage and impaired hepatic/renal function, may require smaller initial doses with 
careful titration.  
Antipsychotics and seizure threshold  
Alper reported the rate of seizures associated with the use of APDs to range 
between 0.3%- 3.5% among patients without epilepsy [70]. The
 
entire class of APDs have 
been found associated with significantly increased seizure incidence (SIR=2.05; 95% CI, 
1.74-2.4). This finding remained significant after the removal of clozapine (SIR=1.35; 
95% CI, 1.09-1.66) but not after the removal of both clozapine and olanzapine (SIR= 
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1.18; 95% CI, .92-1.49), indicating that the observed increase was accounted for largely 
by clozapine and olanzapine [70]. Quetiapine was also associated with increased seizure 
incidence (SIR= 2.05; 95% CI, 1.21-3.23) relative to placebo. The remaining APDs, i.e. 
ziprasidone, aripiprazole and risperidone demonstrated no significant associated with 
seizure incidence (SIR= 1.03; 95% CI, .77-1.35) [70]. In clinical practice, is it possible to 
prescribe APDs in PWE without an increased risk in seizure frequency? Salient data 
include controlled studies in PWE, where the frequency of epileptic seizures was 
compared between two parallel groups, one on APDs and the other without;
 
APD 
prescription was found not to increase seizure frequency [71]. Furthermore, the 
appearance of unusual EEG epileptiform activity and epileptic seizures with the 
introduction of clozapine has been evaluated [72]. Kikuchi et al. enrolled 26 patients with 
treatment resistant schizophrenia and reported that six patients prescribed clozapine 
experienced seizures (mean dose of clozapine at the first occurrence of seizure was 383 
mg/d). Seizures were successfully treated with valproate or lamotrigine without 
discontinuation of clozapine. Successful treatment with clozapine without an increase in 
seizure frequency has been reported in a small case series [73] and case reports [74]. In 
clinical practice, the prescription of APDs does not increase the risk of seizures in PWE 
who are concurrently treated therapeutically with AEDs [75]. Transcranial magnetic 
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stimulation (TMS) has been used to study cortical excitability changes in epilepsy 
including the effect of AED use. A successful response to AED resulted in a decrease in 
cortical excitability and this effect was independent of the type of AED used [76]. The 
authors’ clinical experience indicates that carefully administered APD treatment is safe 
for use in epilepsy. The aim should be to treat with the minimum effective dose. In 
clinically significant Psychoses in PWE, the benefits of APD prescription outweigh the 
increased theoretical probability of seizures in most cases [67].
 
Conclusion 
The association between psychotic disorders and epilepsy remains incompletely 
understood. However, clinical experience and the limited systematic evidence available 
can be drawn on to set up a strategic framework for patient management. The proposed 
strategy is worthy of examination in controlled trials in the future. 
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